About Glycostem Therapeutics

Glycostem Therapeutics is a Netherlands based lifescience company advancing the science of cellular immunotherapy by creating breakthroughs in the expansion and differentiation of hematopoietic stem cells.

Glycostem Therapeutics has developed a new and innovative cell culture system for the ex-vivo generation of clinically relevant amounts of NK-cells.   

Glycostem Therapeutics pursues an open project collaboration policy towards joint development of cellular immunotherapeutics for treatment of leukemia, lymphomas and other forms of cancer.   

Company

Glycostem Therapeutics´core activity is the development of proprietary technology, procedures and products for up-scaling of cellular therapeutics under GMP-conditions, including specialized media for expansion and differentiation of Hematopoietic Stem Cells, GMP-compliant cell culture systems and Standard Operating Procedures.

Glycostem Therapeutics is cooperating with the Departments of Hematology and Laboratory for Hospital Medicine of the University Medical Centre St. Radboud in Nijmegen, the Medical University of Vienna, the University of Minnesota and Erasmus MC / Daniel den Hoed Oncology Center in Rotterdam.

The company was founded in 2007 and is privately owned.

Glycostem Therapeutics' first experimental clinical trial with ex-vivo generated NK-cells for the treatment of AML-patients has started per November 1st, 2011.